Company analysis

PharmaVitae explores Incyte’s prescription pharmaceutical performance and outlook over 2019–29.

Company Analysis: Ionis Pharmaceuticals

PharmaVitae explores Ionis Pharmaceuticals’ prescription pharmaceutical performance and outlook over 2019–29.

Company Analysis: Johnson & Johnson

PharmaVitae explores Johnson & Johnson’s prescription pharmaceutical performance and outlook over 2019–29.

Company Analysis: Kyowa Kirin

PharmaVitae explores Kyowa Kirin’s prescription pharmaceutical performance and outlook over 2019–29.

January 28, 2021

Company Analysis: Lundbeck

PharmaVitae explores Lundbeck’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

Company Analysis: Merck & Co

PharmaVitae explores Merck & Co’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

Company Analysis: Merck KGaA

PharmaVitae explores Merck KGaA’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.

January 25, 2020

Company Analysis: Mitsubishi Tanabe

PharmaVitae explores Mitsubishi Tanabe’s prescription pharmaceutical performance and outlook over 2019–29.

Company Analysis: Novartis

PharmaVitae explores Novartis’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

Company Analysis: Novo Nordisk

PharmaVitae explores Novo Nordisk’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

Company Analysis: Ono Pharmaceutical

PharmaVitae explores Ono Pharmaceutical’s prescription pharmaceutical performance and outlook over 2019–29.

Company Analysis: Otsuka

PharmaVitae explores Otsuka’s prescription pharmaceutical performance and outlook over 2019–29.

January 29, 2020

Company Analysis: Pfizer

PharmaVitae explores Pfizer’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

August 28, 2020

Company Analysis: Regeneron

PharmaVitae explores Regeneron’s prescription pharmaceutical performance and outlook over 2019–29.

Company Analysis: Roche

PharmaVitae explores Roche’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

Company Analysis: Sanofi

PharmaVitae explores Sanofi’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.

Company Analysis: Seagen

PharmaVitae explores Seattle Genetics’ prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.

Company Analysis: Shionogi

PharmaVitae explores Shionogi’s prescription pharmaceutical performance and outlook through to 2029.

Company Analysis: Sumitomo Dainippon

PharmaVitae explores Sumitomo Dainippon’s prescription pharmaceutical performance and outlook over 2019–29.

January 28, 2021

Company Analysis: Takeda

PharmaVitae explores Takeda’s prescription pharmaceutical performance and outlook over 2019–29.

Company Analysis: Teva

PharmaVitae explores Teva’s prescription pharmaceutical performance and outlook over 2019–29.

Company Analysis: UCB

PharmaVitae explores UCB’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts

Company Analysis: United Therapeutics

PharmaVitae explores United Therapeutics’ prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.

Company Analysis: Vertex

PharmaVitae explores Vertex’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.

Immuno-Oncology Deal Trends, 2012–16

$2,995.00

Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated.

April 19, 2017

Japan Pharma Outlook

Datamonitor’s Japan Pharma peer set contains the top 10 companies headquartered in Japan: Takeda Pharmaceuticals, Astellas Pharma, Daiichi Sankyo, Otsuka Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Dainippon Sumitomo, Shionogi & Co and Kyowa Hakko Kirin.

September 28, 2016

Japan Pharma Outlook 2027

PharmaVitae explores and visualizes market dynamics in the Japan Pharma peer set out to 2027* through analysis and in-house sales forecasts for more than 320 products.

July 2, 2018

JP Morgan Healthcare Conference Preview

PharmaVitae previews companies presenting at the JP Morgan Healthcare Conference to be held in San Francisco over 8–11 January 2018.

January 10, 2018

JP Morgan Healthcare Conference Review

The 2018 JP Morgan Healthcare Conference held in San Francisco over 8–11 January 2018 was light on big news and deals, but PharmaVitae picked up on key themes for some of the presenting companies in our coverage universe, which are all experiencing and/or pursuing a change of scene and pace in dealmaking activity.

January 18, 2018

M&A Analysis 2018

PharmaVitae has launched the M&A Outlook 2018 report, click to view the 27 targets that potential acquirers should prioritize based on strategic themes, KOL interviews, and physician surveys.

April 24, 2018